Cargando…

Deciphering the Effects of Injectable Pre-exposure Prophylaxis for Combination Human Immunodeficiency Virus Prevention

Background. A long-acting injectable formulation of rilpivirine (RPV), under investigation as antiretroviral pre-exposure prophylaxis (PrEP), may facilitate PrEP adherence. In contrast, cross-resistance between RPV and nonnucleoside reverse-transcriptase inhibitors comprising first-line antiretrovir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Glaubius, Robert L., Parikh, Urvi M., Hood, Greg, Penrose, Kerri J., Bendavid, Eran, Mellors, John W., Abbas, Ume L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047428/ https://www.ncbi.nlm.nih.gov/pubmed/27703992 http://dx.doi.org/10.1093/ofid/ofw125

Ejemplares similares

Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost‐effectiveness
por: Glaubius, Robert, et al.
Publicado: (2019)

Factors Influencing the Emergence and Spread of HIV Drug Resistance Arising from Rollout of Antiretroviral Pre-Exposure Prophylaxis (PrEP)
por: Abbas, Ume L., et al.
Publicado: (2011)

Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis
por: Fulcher, Jennifer A, et al.
Publicado: (2019)

Is Emtricitabine-Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection Safer Than Aspirin?
por: Kojima, Noah, et al.
Publicado: (2016)

Acceptability and Feasibility of a Pharmacist-Led Human Immunodeficiency Virus Pre-Exposure Prophylaxis Program in the Midwestern United States
por: Havens, Joshua P, et al.
Publicado: (2019)

Drug resistance from preferred antiretroviral regimens for HIV infection in South Africa: A modeling study
por: Abbas, Ume L., et al.
Publicado: (2019)

US Human Immunodeficiency Virus (HIV) Practitioners’ Recommendations Regarding Condomless Sex in the Era of HIV Pre-Exposure Prophylaxis and Treatment as Prevention
por: Schreier, Travis, et al.
Publicado: (2019)

Differentiated Human Immunodeficiency Virus RNA Monitoring in Resource-Limited Settings: An Economic Analysis
por: Negoescu, Diana M., et al.
Publicado: (2017)

Predictors of Human Immunodeficiency Virus Pre-Exposure Prophylaxis (PrEP) Uptake in a Sexual Health Clinic With Rapid PrEP Initiation
por: Wagner, Gabriel A, et al.
Publicado: (2023)

Pre-exposure Prophylaxis Recent Adherence With Real-Time Adherence Feedback and Partner Human Immunodeficiency Virus Self-Testing: A Pilot Trial Among Postpartum Women
por: Joseph Davey, Dvora Leah, et al.
Publicado: (2021)

Human Immunodeficiency Virus Pre-Exposure Prophylaxis Knowledge, Attitudes, and Self-Efficacy Among Family Planning Providers in the Southern United States: Bridging the Gap in Provider Training
por: Ramakrishnan, Aditi, et al.
Publicado: (2022)

Drug Resistance After Failure of WHO Recommended First-Line Antiretroviral Regimen for Adult HIV-1 Infection in South Africa: A Modeling Analysis
por: Ding, Yajun, et al.
Publicado: (2017)

Opportunities to Increase Access to HIV Prevention: Evaluating the Implementation of Pharmacist-Initiated Pre-exposure Prophylaxis in California
por: Hunter, Lauren A, et al.
Publicado: (2023)

Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide for Human Immunodeficiency Virus Preexposure Prophylaxis at a Boston Community Health Center
por: Marcus, Julia L, et al.
Publicado: (2021)

Impact of Tenofovir-Based Pre-exposure Prophylaxis on Biomarkers of Bone Formation, Bone Resorption, and Bone Mineral Metabolism in HIV-Negative Adults
por: Nickolas, Thomas L, et al.
Publicado: (2019)

Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?
por: Parikh, Urvi M., et al.
Publicado: (2022)

Preventive Efficacy of Tenofovir/Emtricitabine Against Severe Acute Respiratory Syndrome Coronavirus 2 Among Pre-Exposure Prophylaxis Users
por: Ayerdi, Oskar, et al.
Publicado: (2020)

Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa
por: Alistar, Sabina S, et al.
Publicado: (2014)

Am I Positive? Improving Human Immunodeficiency Virus Testing in the Era of Preexposure Prophylaxis and Immediate Antiretroviral Therapy Using Machine Learning
por: Zucker, Jason, et al.
Publicado: (2022)

Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention
por: Reidy, Meghan, et al.
Publicado: (2019)

Elucidating Drivers for Variations in the Explosive Human Immunodeficiency Virus Epidemic Among People Who Inject Drugs in Pakistan
por: Lim, Aaron G, et al.
Publicado: (2021)

Health Care–Seeking Behaviors and Perceptions of Provider-Initiated Discussion of Pre-exposure Prophylaxis Among PrEP-Naïve HIV-Negative Men Who Have Sex With Men in Atlanta, Georgia
por: Trost, Susanna L, et al.
Publicado: (2020)

Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa
por: Penrose, Kerri J, et al.
Publicado: (2018)

Incidence and Prevalence of Hepatitis C Virus Among HIV-Negative Gay and Bisexual Men Using HIV Pre-exposure Prophylaxis (PrEP): A Systematic Review and Meta-analysis
por: Traeger, Michael W, et al.
Publicado: (2023)

Community pharmacists’ acceptance of prescribing pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV)
por: Booker, Connor, et al.
Publicado: (2023)

Consensus statement on human immunodeficiency virus pre-exposure prophylaxis in China
por: Xu, Jun-Jie, et al.
Publicado: (2020)

High Prevalence of Anal and Oral High-Risk Human Papillomavirus in Human Immunodeficiency Virus–Uninfected French Men Who Have Sex With Men and Use Preexposure Prophylaxis
por: Mboumba Bouassa, Ralph-Sydney, et al.
Publicado: (2019)

Morbidity and Mortality Among Community-Based People Who Inject Drugs With a High Hepatitis C and Human Immunodeficiency Virus Burden in Chennai, India
por: Mehta, Shruti H., et al.
Publicado: (2016)

Early Experience Implementing Long-Acting Injectable Cabotegravir/Rilpivirine for Human Immunodeficiency Virus-1 Treatment at a Ryan White-Funded Clinic in the US South
por: Collins, Lauren F, et al.
Publicado: (2022)

Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE
por: Atkinson, Andrew, et al.
Publicado: (2020)

Feasibility and Acceptability of Home-Collected Samples for Human Immunodeficiency Virus Preexposure Prophylaxis and Severe Acute Respiratory Syndrome Coronavirus 2 Laboratory Tests in San Francisco Primary Care Clinics
por: Saberi, Parya, et al.
Publicado: (2022)

A Recent Human Immunodeficiency Virus Outbreak Among People Who Inject Drugs in Munich, Germany, Is Associated With Consumption of Synthetic Cathinones
por: Hanke, Kirsten, et al.
Publicado: (2020)

Modelling impact and cost‐effectiveness of oral pre‐exposure prophylaxis in 13 low‐resource countries
por: Pretorius, Carel, et al.
Publicado: (2020)

Public health significance of human immunodeficiency virus pre-exposure and post-exposure prophylaxis
por: Xu, Jun-Jie, et al.
Publicado: (2020)

Hepatitis C Virus Coinfection in People With Human Immunodeficiency Virus in Iran: A Systematic Review and Meta-Analysis
por: Razavi-Amoli, Seyedeh-Kiana, et al.
Publicado: (2022)

AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019
por: Levin, Myron J, et al.
Publicado: (2022)

Same-Day HIV Pre-Exposure Prophylaxis (PrEP) Initiation During Drop-in Sexually Transmitted Diseases Clinic Appointments Is a Highly Acceptable, Feasible, and Safe Model that Engages Individuals at Risk for HIV into PrEP Care
por: Kamis, Kevin F, et al.
Publicado: (2019)

First Demonstration Project of Long-Acting Injectable Antiretroviral Therapy for Persons With and Without Detectable Human Immunodeficiency Virus (HIV) Viremia in an Urban HIV Clinic
por: Christopoulos, Katerina A, et al.
Publicado: (2022)

Low Rates of Contraception Use in Women With Human Immunodeficiency Virus
por: Bhatta, Manasa, et al.
Publicado: (2022)

Potential Impact of Antiretroviral Chemoprophylaxis on HIV-1 Transmission in Resource-Limited Settings
por: Abbas, Ume L., et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_ijpghvu7sbp7th70af29sr5ht2